
US-based Ocuphire Pharma, Inc. develops and commercializes global therapies for various eye disorders.
Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for various eye disorders. Based in Farmington Hills, United States, the company aims to address unmet needs in ophthalmology through innovative treatments. Their research and development efforts target a range of ocular conditions, with the goal of improving patient outcomes globally.
The company has made significant progress in advancing its pipeline, as evidenced by its presentations at prestigious scientific conferences such as the ARVO Annual Meeting. Ocuphire Pharma's lead candidate, APX3330, has garnered attention in the ophthalmology community, indicating potential breakthroughs in eye disorder treatments. The company's participation in investor conferences also suggests growing interest from the financial sector in its developments.

Ocumension Therapeutics

OcuCure Therapeutics

EyePoint

Ocular Therapeutix
ocutx.com

Visiox
visioxpharma.com

Zhaoke Ophthalmology Pharmaceutical

Surface Pharmaceuticals
surfacepharma.com

Eye-Pharma

MediPrint Ophthalmics

Concours Pharmaceuticals

Outpost Medicine

Iacta Pharmaceuticals

Lumos Pharma
lumos-pharma.com

Apexian Pharmaceuticals
apexianpharma.com

Ocudyne
ocudyne.com
Companies similar to Ocuphire Pharma include Ocumension Therapeutics, OcuCure Therapeutics, EyePoint and Ocular Therapeutix.
Ocuphire Pharma was founded in 2018.
Ocuphire Pharma's headquarters is located in Farmington Hills, MI, US.
Ocuphire Pharma's most recent funding round was for $15M (USD) in June 2021.
As of Jun 8, 2021, Ocuphire Pharma has raised a total of $24.6M (USD).
Ocuphire Pharma has 8 employees as of Feb 6, 2024.